{"id":60255,"date":"2016-04-20T22:45:06","date_gmt":"2016-04-20T22:45:06","guid":{"rendered":"http:\/\/www.abnewswire.com\/pressreleases\/?p=60255"},"modified":"2016-04-20T22:45:06","modified_gmt":"2016-04-20T22:45:06","slug":"alzheimers-disease-pipeline-landscape-and-h1-2016-review-report","status":"publish","type":"post","link":"https:\/\/www.abnewswire.com\/pressreleases\/alzheimers-disease-pipeline-landscape-and-h1-2016-review-report_60255.html","title":{"rendered":"Alzheimers Disease Pipeline Landscape and H1 2016 Review Report"},"content":{"rendered":"<div style=\" width:250px; padding:8px 10px 10px 10px; float:right;\"><a href=\"http:\/\/www.getnews.info\/wp-content\/uploads\/2016\/04\/a1461159373.png\" style=\"border:none !important;\" target=\"_blank\" rel=\"nofollow\" ><img decoding=\"async\" class=\"alignnone size-medium wp-image-29\" title=\"image\" src=\"http:\/\/www.getnews.info\/wp-content\/uploads\/2016\/04\/a1461159373.png\" alt=\"\" width=\"219\" style=\"padding:0px 0px 10px 10px; border:0 solid !important;\" \/><\/a><\/p>\n<div class=\"quotes\" style=\" font-weight:bold; font-style:italic;\">\n<div>&#8220;Market Research and Industry Analysis&#8221;<\/div>\n<\/div>\n<\/div>\n<div style=\"font-style:italic; padding:8px 0px;\">ReportsWeb.com adds &#8220;Alzheimer&#8217;s Disease &#8211; Pipeline Review, H1 2016<br \/>\n&#8221; to its research database which provides an overview of the Alzheimer&#8217;s Disease pipeline landscape.<\/div>\n<p style=\"text-align: justify;\"><span>The report provides comprehensive information on the therapeutics under development for Alzheimer&#8217;s Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. <\/span><\/p>\n<p style=\"text-align: justify;\"><span>Additionally, the report provides an overview of key players involved in therapeutic development for Alzheimer&#8217;s Disease and features dormant and discontinued projects.&nbsp;The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.&nbsp;<\/span><\/p>\n<p><strong>Browse more @ &nbsp;<\/strong><a rel=\"nofollow\" href=\"http:\/\/www.reportsweb.com\/alzheimers-disease-pipeline-review-h1-2016\" >http:\/\/www.reportsweb.com\/alzheimers-disease-pipeline-review-h1-2016<\/a><\/p>\n<p><strong>Scope<\/strong><br \/><span>&#8211; The report provides a snapshot of the global therapeutic landscape of Alzheimer&#8217;s Disease<\/span><br \/><span>&#8211; The report reviews pipeline therapeutics for Alzheimer&#8217;s Disease by companies and universities\/research institutes based on information derived from company and industry-specific sources&nbsp;<\/span><br \/><span>&#8211; The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages&nbsp;<\/span><br \/><span>&#8211; The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&amp;D brief, licensing and collaboration details &amp; other developmental activities&nbsp;<\/span><br \/><span>&#8211; The report reviews key players involved Alzheimer&#8217;s Disease therapeutics and enlists all their major and minor projects<\/span><br \/><span>&#8211; The report assesses Alzheimer&#8217;s Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type&nbsp;<\/span><br \/><span>&#8211; The report summarizes all the dormant and discontinued pipeline projects&nbsp;<\/span><br \/><span>&#8211; The report reviews latest news related to pipeline therapeutics for Alzheimer&#8217;s Disease<\/span><\/p>\n<p><strong>Request a Sample copy @&nbsp;<\/strong><a rel=\"nofollow\" href=\"http:\/\/www.reportsweb.com\/inquiry&amp;RW0001188037\/sample\" >http:\/\/www.reportsweb.com\/inquiry&amp;RW0001188037\/sample<\/a><\/p>\n<p><strong>Table of Contents:<\/strong><\/p>\n<p style=\"text-align: justify;\"><span>Introduction&nbsp;<\/span><br \/><span>Alzheimer&#8217;s Disease Overview&nbsp;<\/span><br \/><span>Therapeutics Development&nbsp;<\/span><br \/><span>Alzheimer&#8217;s Disease &#8211; Therapeutics under Development by Companies&nbsp;<\/span><br \/><span>Alzheimer&#8217;s Disease &#8211; Therapeutics under Investigation by Universities\/Institutes&nbsp;<\/span><br \/><span>Alzheimer&#8217;s Disease &#8211; Pipeline Products Glance&nbsp;<\/span><br \/><span>Alzheimer&#8217;s Disease &#8211; Products under Development by Companies&nbsp;<\/span><br \/><span>Alzheimer&#8217;s Disease &#8211; Products under Investigation by Universities\/Institutes&nbsp;<\/span><br \/><span>Alzheimer&#8217;s Disease &#8211; Companies Involved in Therapeutics Development&nbsp;<\/span><br \/><span>Alzheimer&#8217;s Disease &#8211; Therapeutics Assessment&nbsp;<\/span><br \/><span>Drug Profiles&nbsp;<\/span><br \/><span>Alzheimer&#8217;s Disease &#8211; Recent Pipeline Updates&nbsp;<\/span><br \/><span>Alzheimer&#8217;s Disease &#8211; Dormant Projects&nbsp;<\/span><br \/><span>Alzheimer&#8217;s Disease &#8211; Discontinued Products&nbsp;<\/span><br \/><span>Alzheimer&#8217;s Disease &#8211; Product Development Milestones&nbsp;<\/span><br \/><span>Appendix&nbsp;<\/span><\/p>\n<p><span>Place a Purchase order of complete report &nbsp;(Single User PDF &#8211; USD 2500) <strong>@&nbsp;<\/strong><\/span><a rel=\"nofollow\" href=\"http:\/\/www.reportsweb.com\/buy&amp;RW0001188037\/buy\/2500\" >http:\/\/www.reportsweb.com\/buy&amp;RW0001188037\/buy\/2500<\/a><strong><br \/><\/strong><\/p>\n<p><span style='font-size:18px !important;'>Media Contact<\/span><br \/><strong>Company Name:<\/strong> ReportsWeb<br \/><strong>Contact Person:<\/strong> Rajat Sahni<br \/><strong>Email:<\/strong> sales@reportsweb.com<br \/><strong>Phone:<\/strong> +1-646-491-9876<br \/><strong>Country:<\/strong> United States<br \/><strong>Website:<\/strong> <a href=\"http:\/\/www.reportsweb.com\/alzheimers-disease-pipeline-review-h1-2016\" target=\"_blank\" rel=\"nofollow\">http:\/\/www.reportsweb.com\/alzheimers-disease-pipeline-review-h1-2016<\/a><\/p>\n<p><object type=\"text\/html\" data=\"http:\/\/www.reportsweb.com\/alzheimers-disease-pipeline-review-h1-2016\" style=\"width:605px; height:400px;\"><\/object><\/p>\n<p><img decoding=\"async\" src=\"https:\/\/www.abnewswire.com\/press_stat.php?pr=alzheimers-disease-pipeline-landscape-and-h1-2016-review-report\" alt=\"\" width=\"1px\" height=\"1px\" \/><\/p>\n","protected":false},"excerpt":{"rendered":"<p>&#8220;Market Research and Industry Analysis&#8221; ReportsWeb.com adds &#8220;Alzheimer&#8217;s Disease &#8211; Pipeline Review, H1 2016 &#8221; to its research database which provides an overview of the Alzheimer&#8217;s Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for &hellip; <a href=\"https:\/\/www.abnewswire.com\/pressreleases\/alzheimers-disease-pipeline-landscape-and-h1-2016-review-report_60255.html\">Continue reading <span class=\"meta-nav\">&rarr;<\/span><\/a><\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[401],"tags":[],"class_list":["post-60255","post","type-post","status-publish","format-standard","hentry","category-Business"],"_links":{"self":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/60255","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/comments?post=60255"}],"version-history":[{"count":0,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/posts\/60255\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/media?parent=60255"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/categories?post=60255"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.abnewswire.com\/pressreleases\/wp-json\/wp\/v2\/tags?post=60255"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}